4DMedical Shares Slip Into Red YTD as Profit-Taking Stalls Momentum

4DMedical shares (ASX: 4DX) have put up a breathtaking 1,300% rally over the past year, supported by regulatory wins and marquee hospital contracts, yet are now bumping into the reality that even the most compelling growth stories must eventually contend with, that of valuation gravity and profit-taking pressure.

The 4DMedical share price ended today 9.98% lower at A$4.24, capping a bruising five-day stretch that has seen the stock shed 17.83% and slip into negative territory year-to-date, down 6.61%. The pullback marks a sharp reversal for a name that had captivated markets with its lung imaging platform and string of high-profile US commercial wins, yet still trades roughly thirteen times higher than it did twelve months ago. The setup appears to suggest that a cohort of momentum traders and early institutional holders are locking in extraordinary gains, and a valuation framework that remains stretched relative to current revenue and profitability metrics.

What Has Been Moving 4DMedical Shares?

At the heart of 4DMedical’s meteoric rise is CT:VQ, a non-contrast, CT-based ventilation-perfusion imaging solution that in September 2025 became the first and only such technology to receive FDA 510(k) clearance. The regulatory milestone de-risked the company’s core technology and opened the door to reimbursable clinical use across the substantial US pulmonary diagnostics market. CT:VQ joins 4DMedical’s broader suite of lung-function imaging tools, including its XV Lung Ventilation Analysis Software, which had already secured clearances in multiple jurisdictions.

The company has moved quickly to translate regulatory approval into commercial traction. In December 2025, 4DMedical announced a commercial arrangement with Cleveland Clinic, one of the world’s most prestigious healthcare systems, to commence clinical use of CT:VQ. That deal was followed in early 2026 by a contract with Mayo Clinic, another marquee reference site that sparked a sharp single-day rally. Additional agreements with the West Los Angeles VA and Vanderbilt University Medical Center have broadened the installed base and provided clinical validation at leading academic centres.

Yet the financial picture remains one of early-stage commercialisation. For the fiscal year ended August 2024, 4DMedical reported operating revenue of A$3.8 million, up approximately 422% year-on-year but still accompanied by substantial net losses exceeding A$170 million on a trailing twelve-month basis. More recent estimates place annualised revenue in the A$5 million to A$6 million range, a figure dwarfed by the company’s multi-billion-dollar market capitalisation.

To fund its US expansion and commercial scale-up, 4DMedical completed a capital raise of roughly A$150 million in late 2025 and early 2026. The injection strengthened the balance sheet and addressed near-term execution risk, but it also resulted in significant dilution: shares outstanding increased by approximately 34% year-on-year and more than doubled quarter-on-quarter at one point. That dilution has become a focal point for bears, who argue that per-share upside is mathematically capped unless revenue growth accelerates sharply from current levels.

The company has also secured regulatory approvals beyond the United States, including CE mark clearance for the European Union, UK regulatory sign-off, and Canadian approvals. A partnership with pharmaceutical giant GSK has been cited by long-term holders as a medium-term commercial catalyst, though specific financial terms have not been publicly disclosed in detail.

What Lay Ahead

The tension now facing markets is whether 4DMedical’s pullback represents a healthy consolidation that sets up the next leg higher, or the beginning of a more protracted pullback as reality catches up with expectations.

Bulls point to a fundamentally intact growth story. The technology is first-in-class, regulatory hurdles have been cleared, and adoption at Cleveland Clinic, Mayo Clinic, and other leading institutions provides powerful social proof. Each reference site can act as a commercial catalyst, improving sales efficiency and creating a pipeline of additional hospitals.

Revenue growth of more than 400% year-on-year, while from a low base, supports the thesis that 4DMedical is in the early stages of an S-curve adoption trajectory. The strengthened balance sheet removes near-term going-concern risk and provides runway to scale sales teams and expand geographically. Bulls also highlight that meaningful short interest could provide fuel for sharp squeezes on any positive surprise in upcoming quarterly results or new marquee contract announcements.

Bears, however, see a valuation framework that remains disconnected from financial reality. With revenue still in the single-digit millions and annual losses exceeding A$170 million, the company is years away from profitability and dependent on external capital to fund operations. The recent capital raise, while addressing liquidity risk, introduced heavy dilution that caps per-share upside unless earnings ramp even faster. Public disclosures have focused more on contract headlines than on detailed revenue per site or scan volumes, leaving room for scepticism about the financial impact of announced deals.

The sharp rally in 4DX attracted a large cohort of momentum traders and short-term capital, and when that capital exits to lock in profits, it can overwhelm natural long-only demand, especially in a name with limited fundamental support at current prices. The fact that 4DMedical has turned negative year-to-date despite a 1,300% twelve-month gain signals potential momentum exhaustion, and any disappointment in the next quarterly numbers could trigger another leg down from still-elevated levels.

Short interest data from shows 4DMedical as a mid-range but rising shorted name on the ASX, reflecting a segment of the market actively betting against the story. The stock’s high beta and extreme volatility make it uncomfortable for risk-averse holders, who may reduce exposure at signs of weakness, reinforcing downside moves.